Please provide your email address to receive an email when new articles are posted on . Pediatric patients who underwent cataract extraction with primary IOL implantation were found to have better ...

ZUG, Switzerland, January 6, 2025 – Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced ...

Shares of Ohr Pharmaceutical slipped and then bounced back this morning after the biotech announced that a mid-stage study of Squalamine eye drops failed the primary endpoint in reducing the number of ...

Please provide your email address to receive an email when new articles are posted on . A study has challenged the necessity of placebo controls in randomized clinical trials in which visual acuity is ...

Oculis Announces Positive OCS-05 Phase 2 ACUITY Trial in Acute Optic Neuritis, Met Primary Safety Endpoint and Key Secondary Efficacy Endpoints Opening Development Pathways as a Potential ...

Oculis Holding AG, a global biopharmaceutical company purposefully driven to save sight and improve eye care, announced positive topline results with OCS-05 in the phase 2 ACUITY trial, which met the ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced positive topline results with ...

OCS-05 showed a favorable safety and tolerability profile compared to placebo Achieved statistically significant results on key secondary efficacy endpoints compared to placebo, including objective ...